确认PSA值可改善早期中年男性前列腺癌筛查
基于PROBASE试验中45-55岁筛查轮的72157个PSA值,分析确认性PSA检测对减少不必要检查的作用。初次PSA≥3 ng/ml者中38%(95%CI 36,40)确认时PSA<3 ng/ml,45岁组为46%(95%CI 41,51)。45岁确认PSA阳性者6年前列腺癌风险33%,PSA下降者7.0%(风险比4.68,CI 2.55,8.59)。
要点
- 初次PSA≥3 ng/ml者中38%确认时PSA<3 ng/ml。
- 45岁组确认PSA下降比例46%,高于50岁组的34%。
- 45岁确认PSA阳性者6年PCa风险33%,PSA下降者7.0%。
核心结论
- 早期中年男性PSA升高常见,筛查中启动诊断检查前应确认PSA。
研究设计与样本
- 分析PROBASE试验中45-55岁筛查轮的72157个PSA值。
- 阳性定义为初次或确认PSA≥3 ng/ml。
主要发现
- 共2782次初次PSA和2702次(97%)确认PSA检测。
- 初次PSA≥3 ng/ml者中38%(95%CI 36,40)确认时PSA<3 ng/ml。
- 45岁组确认PSA下降比例46%(95%CI 41,51),50岁组34%(95%CI 31,38)。
- PSA重复检测中位时间28天(IQR 20,39),中位变化-0.5 ng/ml(IQR -1.3,+0.06)。
- 45岁确认PSA阳性者6年PCa风险33%,PSA下降者7.0%(风险比4.68,CI 2.55,8.59)。
关键数值与推荐
- PSA阳性阈值定义为≥3 ng/ml。
- 确认PSA下降定义为确认时PSA<3 ng/ml。
临床怎么用
- 筛查中初次PSA≥3 ng/ml时,启动诊断检查前应重复PSA确认。
- 重复PSA可减少立即进一步诊断检查。
局限性
- 主要局限性为活检信息不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: To assess the effectiveness of a confirmatory prostate-specific antigen (PSA) test as a safeguard against unnecessary work-up and to improve the specificity of prostate cancer (PCa) screening. METHODS: Overall, 72,157 PSA values corresponding to screening rounds at age 45-55 yr in the PROBASE trial were analyzed. Positive PSA tests were reported as the proportion of men with an initial or confirmatory PSA ≥3 ng/ml. The cumulative PCa number over 6 yr was described for men with and without confirmatory PSA decrease at baseline screening (age 45 yr). Sankey diagrams were plotted to illustrate changes in PSA values over 10 yr with 2-yearly PSA screening. KEY FINDINGS AND LIMITATIONS: Overall, 2782 initial PSAs and 2702 (97%) confirmatory PSAs were observed. A total of 38% (95% confidence interval [CI] 36, 40) of men with initial PSA ≥3 ng/ml had a PSA <3 ng/ml at confirmatory testing. Estimates differed by age and screening round: 46% (95% CI 41, 51) in 45-yr-olds and 34% (95% CI 31, 38) in 50-yr-olds. PSA was repeated at a median of 28 d (interquartile range [IQR] 20, 39). Median change was -0.5 ng/ml (IQR -1.3, +0.06). PCa risk at 6 yr was 33% in those with confirmed PSA and 7.0% in those with PSA decrease at age 45 yr (risk ratio 4.68, CI 2.55, 8.59). The main limitation is incomplete biopsy information. CONCLUSION: PSA elevations in early-middle-aged men are common and PSA should be confirmed before initiating diagnostic work-up in a screening setting. CLINICAL IMPLICATIONS: Repeating PSA before initiating diagnostic work-up reduces immediate further diagnostics.
引用
- Krilaviciute A, Becker N, Carlsson SV, et al. Confirmation of Prostate-specific Antigen (PSA) Values Improves Prostate Cancer Screening in Early Middle-Aged Men - Data from the PROBASE Trial. Eur Urol. 2026. PMID: 42442974. doi:10.1016/j.eururo.2026.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。